Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy

George Mellgard,Nathaniel Saffran,Zakaria Chakrani,Stephen McCroskery,Nicole Taylor,Mann Patel,Bobby Liaw,Matthew Galsky,William Oh,Che-Kai Tsao,Vaibhav Patel
DOI: https://doi.org/10.1097/coc.0000000000001115
2024-09-26
American Journal of Clinical Oncology
Abstract:Androgen receptor targeted therapies (ARTs) are widely preferred over taxane chemotherapy due to their good tolerability and similar efficacy. However, there is a paucity of data that support the use of ART therapy or describe end-of-life (EOL) outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) with reduced performance status (PS) (European Cooperative Oncology Group [ECOG] ≥2).
oncology
What problem does this paper attempt to address?